Nextgen Bioscience Inc. - Statement of Beneficial Ownership (SC 13D)
07 Décembre 2007 - 8:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
NEXTGEN BIOSCIENCE INC.
(Name of Issuer)
Shares of Common Stock, par value $0.001 per share
(Title of Class of Securities)
65338 N 10 5
(CUSIP Number)
Lars Christiansen
46 Aldgate High Street
London, England EC3N 1AL.
+44 207 744 7711
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
NOVEMBER 27, 2007
(Date of Event Which
Requires Filing of this Statement)
If the filing person has previously filed a statement on
Schedule 13G to report the acquisition which is
the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or
13d-1
(g), check the following box [ ].
The information required in the remainder of this cover page
shall not be deemed to be “filed” for the
purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the
liabilities of that section of the Act but shall be subject to all other
provisions of the Act.
|
1.
|
Names of Reporting
Person:
Oxon Life Science Limited
|
|
|
I.R.S. Identification Nos. of above person
(entities only):
|
|
|
|
|
|
|
|
2.
|
Check the Appropriate Box if a Member of a
Group (See Instructions)
|
|
(a)
|
[_]
|
|
(b)
|
[X]
|
|
|
|
|
3.
|
SEC Use Only:
|
|
|
|
|
|
|
|
4.
|
Source of Funds (See
Instructions):
OO
|
|
|
|
|
|
|
|
5.
|
Check if Disclosure of Legal Proceedings is
Required Pursuant to Items 2(d) or 2(e):
|
|
|
|
|
|
|
|
6.
|
Citizenship or Place of
Organization:
St Kitts & Nevis,
West Indies
|
|
|
|
Number of Shares Beneficially by Owned by Each Reporting Person
With:
|
7.
|
Sole Voting Power:
|
Nil
|
|
|
|
|
|
8.
|
Shared Voting Power:
|
14,000,000 Shares
|
|
|
|
|
|
9.
|
Sole Dispositive Power:
|
Nil
|
|
|
|
|
|
10.
|
Shared Dispositive Power:
|
14,000,000 Shares
|
|
11.
|
Aggregate Amount Beneficially Owned by Each
Reporting Person:
14,000,000
Shares
|
|
|
|
|
12.
|
Check if the Aggregate Amount in Row (11)
Excludes Certain Shares (See Instructions):
|
|
|
|
|
13.
|
Percent of Class Represented by Amount in Row
(11):
10.86%
|
|
|
|
|
14.
|
Type of Reporting Person (See
Instructions):
CO
|
Page 2 of 7
|
1.
|
Names of Reporting
Person:
Lars Christiansen
|
|
|
I.R.S. Identification Nos. of
above person (entities only):
|
|
|
|
|
|
|
|
2.
|
Check the Appropriate Box if a
Member of a Group (See Instructions)
|
|
(a)
|
[_]
|
|
(b)
|
[X]
|
|
|
|
|
3.
|
SEC Use Only:
|
|
|
|
|
|
|
|
4.
|
Source of Funds (See
Instructions):
OO
|
|
|
|
|
|
|
|
5.
|
Check if Disclosure of Legal
Proceedings is Required Pursuant to Items 2(d) or 2(e):
|
|
|
|
|
|
|
|
6.
|
Citizenship or Place of
Organization:
England
|
|
|
|
Number of Shares Beneficially by Owned by Each Reporting Person
With:
|
7.
|
Sole Voting Power:
|
Nil
|
|
|
|
|
|
8.
|
Shared Voting Power:
|
14,000,000 Shares
|
|
|
|
|
|
12.
|
Sole Dispositive Power:
|
Nil
|
|
|
|
|
|
13.
|
Shared Dispositive Power:
|
14,000,000 Shares
|
|
14.
|
Aggregate Amount Beneficially
Owned by Each Reporting Person:
14,000,000 Shares
|
|
|
|
|
12.
|
Check if the Aggregate Amount in
Row (11) Excludes Certain Shares (See Instructions):
|
|
|
|
|
15.
|
Percent of Class Represented by
Amount in Row
(11):
10.86%
|
|
|
|
|
16.
|
Type of Reporting Person (See
Instructions):
IN
|
Page 3 of 7
ITEM
1. SECURITY AND
ISSUER.
The class of equity securities to which this statement relates
is shares of common stock, par value $0.001 per share (the “Shares”), of NextGen
Bioscience Inc., a Nevada corporation (the “Issuer”). The principal executive
offices of the Issuer are located at 46 Aldgate High Street, London, England,
EC3N 1AL.
ITEM
2. IDENTITY AND
BACKGROUND
|
A.
|
Name of Persons filing this Statement:
|
|
|
|
|
|
This statement is filed by (i) Oxon Life Science Limited
(“Oxon”) and (ii) Lars Christiansen, the principal shareholder and sole
director and officer of Oxon. Oxon and Mr. Christiansen are collectively
referred to as the “Reporting Persons”.
|
|
|
|
|
B.
|
Residence or Business Address:
|
|
|
|
|
|
The business address of the Reporting Persons is Donegan,
Zetlands, Nevis, St Kitts & Nevis, West Indies.
|
|
|
|
|
C.
|
Present Principal Occupation and
Employment:
|
|
|
|
|
|
Oxon is an investment holding company. Mr. Christiansen
is the principal shareholder and sole director and officer of
Oxon.
|
|
|
|
|
D.
|
Criminal Proceedings:
|
|
|
|
|
|
The Reporting Persons have not been convicted in any
criminal proceeding (excluding traffic violations or similar misdemeanors)
during the last five years.
|
|
|
|
|
E.
|
Civil Proceedings:
|
|
|
|
|
|
The Reporting Persons have not been a party to any civil
proceeding of a judicial or administrative body of competent jurisdiction
and, as a result of such proceeding, was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or
finding any violation with respect to such laws.
|
|
|
|
|
F.
|
Citizenship:
|
|
|
|
|
|
Oxon is a corporation incorporated pursuant to the laws
of St. Kitts & Nevis, West Indies. Mr. Christiansen is a citizen of
England.
|
ITEM
3. SOURCE AND AMOUNT
OF FUNDS OR OTHER CONSIDERATION
On November 27, 2007, the Issuer acquired certain intellectual
property assets and undertakings relating to the development of therapies for
the treatment of certain types of cancer (the “Assets”) from Oxon in
consideration for the issuance of an aggregate of 14,000,000 Shares of the
Issuer. Mr. Christiansen is the principal shareholder and sole director and
officer of Oxon and thus may be deemed to share dispositive and voting power
over the Shares of the Issuer held by Oxon.
Page 4 of 7
ITEM
4. PURPOSE OF
TRANSACTION
On November 27, 2007, Oxon was issued 14,000,000 Shares by the
Issuer in connection with the acquisition of the Assets from Oxon. The
acquisition represented a change in the principal business of the Issuer to a
biotechnology company focused on the development and commercialization of novel
therapeutic proteins that disrupt the advance of life-threatening cancers with a
focus on prostate and breast cancer. In connection with the acquisition, the
sole director and officer of the Issuer resigned from the company and two
persons nominated by Oxon were appointed directors and officers of the Issuer.
The Reporting Persons acquired the Shares of the Issuer for
investment purposes. Depending on market conditions and other factors, the
Reporting Persons may acquire additional Shares of the Issuer as the Reporting
Persons may deem appropriate, whether in open market purchases, privately
negotiated transactions or otherwise. The Reporting Persons also reserve the
right to dispose of some or all of such Shares in the open market, in privately
negotiated transactions to third parties or otherwise.
Other than as set forth herein, the Reporting Persons do not
have any current plans or proposals which would relate to or would result in:
|
(a)
|
the acquisition by any person of additional securities of
the Issuer, or the disposition of securities of the Issuer;
|
|
|
|
|
(b)
|
any extraordinary corporate transaction, such as a
merger, reorganization or liquidation, involving the Issuer or any of its
subsidiaries;
|
|
|
|
|
(c)
|
a sale or transfer of a material amount of the assets of
the Issuer or any of its subsidiaries;
|
|
|
|
|
(d)
|
any change in the present board of directors or
management of the Issuer, including any plans or proposals to change the
number or term of directors or to fill any existing vacancies on the
board;
|
|
|
|
|
(e)
|
any material change in the present capitalization or
dividend policy of the Issuer;
|
|
|
|
|
(f)
|
any other material change in the Issuer's business or
corporate structure including, but not limited to, if the Issuer is a
registered closed-end investment company, any plans or proposals to make
any changes in its investment policy for which a vote is required by
Section 13 of the Investment Company Act of 1940;
|
|
|
|
|
(g)
|
changes in the Issuer's charter, bylaws or instruments
corresponding thereto or other actions which may impede acquisition of
control of the Issuer by any person;
|
|
|
|
|
(h)
|
causing a class of securities of the Issuer to be
delisted from a national securities exchange or to cease to be authorized
to be quoted in an inter-dealer quotation system of a registered national
securities association;
|
|
|
|
|
(i)
|
a class of equity securities of the Issuer becoming
eligible for termination of registration pursuant to Section 12(g)(4) of
the Act; or
|
|
|
|
|
(j)
|
any action similar to any of those enumerated
above.
|
Page 5 of 7
ITEM
5. INTEREST IN
SECURITIES OF THE ISSUER
|
a)
|
Beneficial Ownership.
|
|
|
|
|
|
The Reporting Persons beneficially own 14,000,000 Shares
of the Issuer, representing approximately 10.86% of the Issuer’s issued
and outstanding Shares (based upon 128,897,568 Shares of the Issuer
outstanding as at November 30, 2007). The Reporting Persons share voting
and dispositive power over these Shares.
|
|
|
|
|
b)
|
Transactions Within the Past 60
Days.
|
|
|
|
|
|
Except as noted herein, the Reporting Persons have not
effected any other transactions in the Issuer's securities, including the
Shares of the Issuer, within sixty (60) days preceding the date
hereof.
|
|
|
|
|
c)
|
Certain Rights of Other Persons.
|
|
|
|
|
|
Not applicable.
|
|
ITEM 6.
|
CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR
RELATIONSHIPS
WITH RESPECT TO SECURITIES OF THE ISSUER
|
The Reporting Persons do not have any contract, arrangement,
understanding or relationship with respect to securities of the Issuer
including, but not limited to, transfer or voting of any of the securities,
finder's fees, joint ventures, loan or option arrangements, puts or calls,
guarantees of profits, division of profits or loss, or the giving or withholding
of proxies. Further, the Reporting Persons have not pledged securities of the
Issuer nor are the securities of the Issuer held by the Reporting Persons
subject to a contingency, the occurrence of which would give another person
voting power or investment power over such securities.
ITEM
7. MATERIAL TO BE
FILED AS EXHIBITS
(1)
Filed as an exhibit to our Current Report on
Form 8-K filed with the SEC on October 17, 2007.
Page 6 of 7
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
|
Dated: December 6, 2007
|
|
|
|
OXON LIFE SCIENCE LIMITED
|
|
|
|
|
|
/s/ Lars Christiansen
|
|
|
Per: ____________________________________
|
|
|
Lars
Christiansen, Director
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Lars Christiansen
|
|
|
____________________________________
|
|
|
Lars
Christiansen
|
Page 7 of 7
NxGen Brands (CE) (USOTC:NXGB)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
NxGen Brands (CE) (USOTC:NXGB)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
